Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 25Active not recruiting 5Terminated 4Recruiting 3Not yet recruiting 1

Sponsor Class

OTHER 25INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1

Interventions

Injections 41Carboplatin 34Cisplatin 24Capecitabine 24Paclitaxel 23Docetaxel 23pembrolizumab 21Oxaliplatin 21Gemcitabine 20Pemetrexed 19Bevacizumab 18Fluorouracil 13Irinotecan 12Cyclophosphamide 12osimertinib 9Nivolumab 8Dexamethasone 8tislelizumab 7Topotecan 7Leucovorin 7Doxorubicin 7130-nm albumin-bound paclitaxel 7venetoclax 6toripalimab 6regorafenib 6lenvatinib 6fludarabine 6Rituximab 6Cetuximab 6daratumumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × INDUSTRY × S 1 (combination) × Clear all
NCT06571461 2024-08-27

Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer

CSPC Ouyi Pharmaceutical Co., Ltd.

Phase 3 Not yet recruiting
408 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡